Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database

Modern Rheumatology

Volumn 28, Issue 3, 2018, Pages 435-443

  Atsumi, Tatsuya ^a   Ando, Yoshiaki ^b   Matsuda, Shinichi ^b   Tomizawa, Shiho ^b   Tanaka, Riwa ^b   Takagi, Nobuhiro ^b   Nakasone, Ayako ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adverse events; infections; rheumatoid arthritis; text mining; tocilizumab

Indexed keywords

ABATACEPT; ACTARIT; ADALIMUMAB; AURANOFIN; AZATHIOPRINE; BUCILLAMINE; C REACTIVE PROTEIN; CYCLOSPORINE; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; IGURATIMOD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; THIOMALATE SODIUM; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BODY MASS; BODY TEMPERATURE; CELLULITIS; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DATA MINING; DIVERTICULITIS; DYSPNEA; ELECTRONIC MEDICAL RECORD; FEMALE; FEVER; GASTROINTESTINAL INFECTION; HUMAN; INFECTION; JAPANESE (CITIZEN); LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; PAIN; PERITONITIS; PLEURA EFFUSION; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SKIN INFECTION; SWELLING; URINARY TRACT INFECTION; YOUNG ADULT; CLINICAL TRIAL; JAPAN; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FEVER; HUMANS; JAPAN; MALE; MIDDLE AGED; PRODROMAL SYMPTOMS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 85029404451     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2017.1366007     Document Type: Article

References (26)

1. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
2. Singh JA, Saag KG, Bridges SL, Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68:1–26.
3. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
4. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J., Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2008;68:1580–4.
5. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40:768–80.
6. Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res. 2014;66:1653–61.
7. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41:15–23.
8. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731–40.
9. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T., Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–64.
10. Harpaz R, Dumouchel W, Shah NH, Madigan D, Ryan P, Friedman C., Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91:1010–21.
11. Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, et al. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des Devel Ther. 2015;9:3031–41.
12. Dore DD, Seeger JD, Arnold CK., Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019–27.
13. Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, et al. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol. 2015;42:1368–75.
14. LePendu P, Iyer SV, Fairon C, Shah NH., Annotation analysis for testing drug safety signals using unstructured clinical notes. J Biomed Semantics. 2012;3(Suppl. 1):S5.
15. Harpaz R, Vilar S, Dumouchel W, Salmasian H, Haerian K, Shah NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20:413–19.
16. Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH., Mining clinical text for signals of adverse drug-drug interactions. J Am Med Inform Assoc. 2014;21:353–62.
17. Roitmann E, Eriksson R, Brunak S., Patient stratification and identification of adverse event correlations in the space of 1190 drug related adverse events. Front Physiol. 2014;5:332.
18. Imai T, Aramaki E, Kajino M, Miyo K, Onogi Y, Ohe K., Finding malignant findings from radiological reports using medical attributes and syntactic information. Stud Health Technol Inform. 2007;129:540–4.
19. Gonzalez GH, Tahsin T, Goodale BC, Greene AC, Greene CS., Recent advances and emerging applications in text and data mining for biomedical discovery. Brief Bioinform. 2016;17:33–42.
20. Iqbal E, Mallah R, Jackson RG, Ball M, Ibrahim ZM, Broadbent M, et al. Identification of adverse drug events from free text electronic patient records and information in a large mental health case register. PLoS One. 2015;10:e0134208.
21. Chin CY, Weng MY, Lin TC, Cheng SY, Yang YH, Tseng VS., Mining disease risk patterns from nationwide clinical databases for the assessment of early rheumatoid arthritis risk. PLoS One. 2015;10:e0122508.
22. Bruland P, McGilchrist M, Zapletal E, Acosta D, Proeve J, Askin S, et al. Common data elements for secondary use of electronic health record data for clinical trial execution and serious adverse event reporting. BMC Med Res Methodol. 2016;16:159.
23. Brown EG, Wood L, Wood S., The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–17.
24. Porter RS, Kaplan JL, eds. The Merck manual of diagnosis and therapy. 19th ed. Kenilworth (NJ): Merck Publishing; 2011.
25. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.
26. Matsuda S, Aoki K, Kawamata T, Kimotsuki T, Kobayashi T, Kuriki H, et al. Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS One. 2015;10:e0126413.